Latest News - Page 2 of 41 - Oklahoma Society of Clinical Oncology

CMS finalizes rule which forces drug manufacturers to provide the list price for their products in direct-to-consumer ads.

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

Read More

Merck announces new FDA approval for KEYTRUDA

Merck announces new FDA approval for KEYTRUDA Merck is pleased to announce that KEYTRUDA, in combination with axitinib, has been approved by the FDA for the first-line treatment of patients with advanced renal cell carcinoma (RCC). PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients FDA=Food and Drug Administration; PD-L1=programmed […]

Read More

AstraZeneca announces new CMS J-code assigned for IMFINZI®

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS). Effective for dates of services on or after January 1, 2019, J-Code J9173 can be used to identify IMFINZI® (durvalumab) when billing across settings of care as noted in the […]

Read More

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients With Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)

Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and […]

Read More

AstraZeneca announces that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code.

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS). Effective for dates of services on or after January 1, 2019, the following code can be used to identify IMFINZI® (durvalumab) when billing across settings of care as noted in […]

Read More

Astellas Pharma announces FDA approval of XOSPATA.

Astellas Pharma US, Inc. is pleased to announce that the FDA has approved XOSPATA. XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.1 An estimated 37% of AML patients have a FLT3 mutation and […]

Read More

(FDA) approves a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use.

On November 16, 2018, the U.S. Food and Drug Administration (FDA) approved a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use. The new indication is as follows: Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not […]

Read More

IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS). Effective for dates of services on or after January 1, 2019, the following code can be used to identify IMFINZI® (durvalumab) when billing across settings of care as noted in […]

Read More

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult Patients With Hepatocellular Carcinoma (HCC)

Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of patients with HCC who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description […]

Read More

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) Announced

Merck is pleased to announce that KEYTRUDA in combination with carboplatin and either paclitaxel or nab-paclitaxel has been approved by the FDA for the first-line treatment of patients with metastatic squamous NSCLC. KEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the First-line treatment of patients with metastatic nonsquamous NSCLC, with no […]

Read More